Cost-Effectiveness of Strategies to Personalize the Selection of P2Y 12 Inhibitors in Patients with Acute Coronary Syndrome

ConclusionCost-effective strategies to personalize P2Y12 inhibition in ACS include clopidogrel +phenotype and genotype + liberal ticagrelor. Universal ticagrelor may be considered cost-effective at a higher WTP threshold ($150,000/QALY). Genotype + liberal ticagrelor exhibited the highest acceptability compared to clopidogrel + phenotype over the widest range of WTP thresholds and may be preferred.

http://link.springer.com/10.1007/s10557-019-06896-8

Source: Cardiovascular Drugs and Therapy - July 30, 2019 Category: Cardiology Source Type: research